1. Opening Hook
In a market where everyone wants to be “asset-light,” HVAX showed up saying, “We build mission-critical rooms that can’t fail.”
Then it casually announced a ₹2.6 crore acquisition… and promised to make it 15x bigger.
Margins dipped, pipelines exploded, and management spent half the call explaining that HVAX is not your usual EPC contractor.
Apparently, they don’t build buildings—they build sterile air, validated pressure, and regulatory peace of mind.
Between pharma clean rooms, hospital ambitions, and semiconductor curiosity, HVAX sounds confident.
Almost too confident.
Read on—because this concall was less about HVAC ducts and more about whether diversification saves margins or dilutes focus. 😏
2. At a Glance
- Revenue ₹62.8 Cr: Up 35% YoY—execution engine clearly humming.
- EBITDA ₹8.53 Cr: Grew 19%, but margins blinked first.
- PAT ₹4.94 Cr: Up 29%—profits still showed up, thankfully.
- Order book ₹350 Cr: Two years of work already booked.
- Pipeline ₹650 Cr: 20–25% conversion—optimism with a disclaimer.
3. Management’s Key Commentary
“We are scaling through higher-value engagements, not volume.”
(Translation: Fewer projects, better cheques.) 😏
“Our growth quality has improved.”
(Translation: Margins dipped, but trust us—it’s strategic.)
“Krew Instruments gives us entry into healthcare infrastructure.”
(Translation: Small company, big hospital dreams.)
“This acquisition is about synergies, not size.”
(Translation: Yes, it’s tiny—but it unlocks tenders.)
“We expect 35% growth for the next couple of years.”
(Translation: Pharma capex better not slow.)
“Export margins are better than domestic.”
(Translation: India is competitive; GCC pays better.)
4. Numbers Decoded
Metric | Reported
